Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.89
+0.26 (1.91%)
May 16, 2025, 10:12 AM - Market open
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Arcutis Biotherapeutics stock ranges from a low of $15 to a high of $21. The average analyst price target of $18.8 forecasts a 35.35% increase in the stock price over the next year.
Price Target: $18.80 (+35.35%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 9, 2025.
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +43.99% | Apr 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +36.79% | Apr 3, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +43.99% | Apr 3, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $16 → $19 | Strong Buy | Maintains | $16 → $19 | +36.79% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
317.26M
from 196.54M
Increased by 61.42%
Revenue Next Year
437.54M
from 317.26M
Increased by 37.91%
EPS This Year
-0.66
from -1.16
EPS Next Year
0.25
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 344.3M | 476.7M | 764.5M | ||
| Avg | 317.3M | 437.5M | 593.9M | ||
| Low | 286.2M | 392.0M | 443.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 75.2% | 50.3% | 74.7% | ||
| Avg | 61.4% | 37.9% | 35.7% | ||
| Low | 45.6% | 23.6% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.50 | 1.42 | 2.82 | ||
| Avg | -0.66 | 0.25 | 1.34 | ||
| Low | -0.79 | -0.25 | 0.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,015.9% | ||
| Avg | - | - | 428.0% | ||
| Low | - | - | -49.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.